RIPK2-IN-2

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562098

CAS#: 1581270-11-2

Description: RIPK2-IN-2 is a potent and selective inhibitor of receptor interacting protein-2 (RIP2) kinase.

Chemical Structure

img
RIPK2-IN-2
CAS# 1581270-11-2
Instruction

Theoretical Analysis

MedKoo Cat#: 562098
Name: RIPK2-IN-2
CAS#: 1581270-11-2
Chemical Formula: C21H28N4O4S
Exact Mass: 432.18
Molecular Weight: 432.530
Elemental Analysis: C, 58.31; H, 6.53; N, 12.95; O, 14.80; S, 7.41

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: RIPK2-IN-2; RIPK2 IN 2; RIPK2IN2; RIPK2 inhibitor-2; RIPK2 inhibitor 2;

IUPAC/Chemical Name: 6-[(1,1-Dimethylethyl)sulfonyl]-N-(4,5-dimethyl-1H-pyrazol-3-yl)-7-(2-methoxyethoxy)-4-quinolinamine

InChi Key: QODPGRHWJBWTJC-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H28N4O4S/c1-13-14(2)24-25-20(13)23-16-7-8-22-17-12-18(29-10-9-28-6)19(11-15(16)17)30(26,27)21(3,4)5/h7-8,11-12H,9-10H2,1-6H3,(H2,22,23,24,25)

SMILES Code: COCCOC1=C(S(=O)(C(C)(C)C)=O)C=C2C(NC3=NNC(C)=C3C)=CC=NC2=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 432.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Suebsuwong C, Pinkas DM, Ray SS, Bufton JC, Dai B, Bullock AN, Degterev A, Cuny GD. Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors. Bioorg Med Chem Lett. 2018 Jan 31. pii: S0960-894X(18)30054-4. doi: 10.1016/j.bmcl.2018.01.044. [Epub ahead of print] PubMed PMID: 29409752.

2: He X, Da Ros S, Nelson J, Zhu X, Jiang T, Okram B, Jiang S, Michellys PY, Iskandar M, Espinola S, Jia Y, Bursulaya B, Kreusch A, Gao MY, Spraggon G, Baaten J, Clemmer L, Meeusen S, Huang D, Hill R, Nguyen-Tran V, Fathman J, Liu B, Tuntland T, Gordon P, Hollenbeck T, Ng K, Shi J, Bordone L, Liu H. Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases. ACS Med Chem Lett. 2017 Sep 27;8(10):1048-1053. doi: 10.1021/acsmedchemlett.7b00258. eCollection 2017 Oct 12. PubMed PMID: 29057049; PubMed Central PMCID: PMC5641954.

3: Talreja J, Talwar H, Ahmad N, Rastogi R, Samavati L. Dual Inhibition of Rip2 and IRAK1/4 Regulates IL-1β and IL-6 in Sarcoidosis Alveolar Macrophages and Peripheral Blood Mononuclear Cells. J Immunol. 2016 Aug 15;197(4):1368-78. doi: 10.4049/jimmunol.1600258. Epub 2016 Jul 11. PubMed PMID: 27402699; PubMed Central PMCID: PMC4975961.

4: Haile PA, Votta BJ, Marquis RW, Bury MJ, Mehlmann JF, Singhaus R Jr, Charnley AK, Lakdawala AS, Convery MA, Lipshutz DB, Desai BM, Swift B, Capriotti CA, Berger SB, Mahajan MK, Reilly MA, Rivera EJ, Sun HH, Nagilla R, Beal AM, Finger JN, Cook MN, King BW, Ouellette MT, Totoritis RD, Pierdomenico M, Negroni A, Stronati L, Cucchiara S, Ziółkowski B, Vossenkämper A, MacDonald TT, Gough PJ, Bertin J, Casillas LN. The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase. J Med Chem. 2016 May 26;59(10):4867-80. doi: 10.1021/acs.jmedchem.6b00211. Epub 2016 May 4. PubMed PMID: 27109867.

5: Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, Düker G, Bettels R, Rohrbach M, Kugathasan S, Chapel H, Keshav S, Elkadri A, Platt N, Muise AM, Koletzko S, Xavier RJ, Marquardt T, Powrie F, Wraith JE, Gyrd-Hansen M, Platt FM, Uhlig HH. Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease. Gut. 2017 Jun;66(6):1060-1073. doi: 10.1136/gutjnl-2015-310382. Epub 2016 Mar 7. PubMed PMID: 26953272; PubMed Central PMCID: PMC5532464.

6: Wex K, Schmid U, Just S, Wang X, Wurm R, Naumann M, Schlüter D, Nishanth G. Receptor-Interacting Protein Kinase-2 Inhibition by CYLD Impairs Antibacterial Immune Responses in Macrophages. Front Immunol. 2016 Jan 19;6:650. doi: 10.3389/fimmu.2015.00650. eCollection 2015. PubMed PMID: 26834734; PubMed Central PMCID: PMC4717182.

7: Han NR, Moon PD, Jeong HJ, Kim HM. Hydrogen sulfide diminishes the levels of thymic stromal lymphopoietin in activated mast cells. Arch Dermatol Res. 2016 Mar;308(2):103-13. doi: 10.1007/s00403-016-1619-x. Epub 2016 Jan 20. PubMed PMID: 26791024.

8: Lind KF, Østerud B, Hansen E, Jørgensen TØ, Andersen JH. The immunomodulatory effects of barettin and involvement of the kinases CAMK1α and RIPK2. Immunopharmacol Immunotoxicol. 2015;37(5):458-64. doi: 10.3109/08923973.2015.1082584. PubMed PMID: 26466644.

9: Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L. Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity. Bioorg Med Chem. 2015 Nov 1;23(21):7000-6. doi: 10.1016/j.bmc.2015.09.038. Epub 2015 Sep 25. PubMed PMID: 26455654.

10: Canning P, Ruan Q, Schwerd T, Hrdinka M, Maki JL, Saleh D, Suebsuwong C, Ray S, Brennan PE, Cuny GD, Uhlig HH, Gyrd-Hansen M, Degterev A, Bullock AN. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors. Chem Biol. 2015 Sep 17;22(9):1174-84. doi: 10.1016/j.chembiol.2015.07.017. Epub 2015 Aug 27. PubMed PMID: 26320862; PubMed Central PMCID: PMC4579271.

11: Qian YJ, Wang X, Gao YF, Duan N, Huang XF, Sun FF, Han XD, Wang WM. Cigarette Smoke Modulates NOD1 Signal Pathway and Human β Defensins Expression in Human Oral Mucosa. Cell Physiol Biochem. 2015;36(2):457-73. doi: 10.1159/000430112. Epub 2015 May 11. PubMed PMID: 25968832.

12: Xu J, Jiang C, Zhu W, Wang B, Yan J, Min Z, Geng M, Han Y, Ning Q, Zhang F, Sun J, Meng L, Lu S. NOD2 pathway via RIPK2 and TBK1 is involved in the aberrant catabolism induced by T-2 toxin in chondrocytes. Osteoarthritis Cartilage. 2015 Sep;23(9):1575-85. doi: 10.1016/j.joca.2015.04.016. Epub 2015 Apr 24. PubMed PMID: 25917637.

13: Nachbur U, Stafford CA, Bankovacki A, Zhan Y, Lindqvist LM, Fiil BK, Khakham Y, Ko HJ, Sandow JJ, Falk H, Holien JK, Chau D, Hildebrand J, Vince JE, Sharp PP, Webb AI, Jackman KA, Mühlen S, Kennedy CL, Lowes KN, Murphy JM, Gyrd-Hansen M, Parker MW, Hartland EL, Lew AM, Huang DC, Lessene G, Silke J. A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production. Nat Commun. 2015 Mar 17;6:6442. doi: 10.1038/ncomms7442. PubMed PMID: 25778803.

14: Singh V, Holla S, Ramachandra SG, Balaji KN. WNT-inflammasome signaling mediates NOD2-induced development of acute arthritis in mice. J Immunol. 2015 Apr 1;194(7):3351-60. doi: 10.4049/jimmunol.1402498. Epub 2015 Feb 25. PubMed PMID: 25717000.

15: Wu J, Zhang Y, Xin Z, Wu X. The crosstalk between TLR2 and NOD2 in Aspergillus fumigatus keratitis. Mol Immunol. 2015 Apr;64(2):235-43. doi: 10.1016/j.molimm.2014.11.021. Epub 2014 Dec 27. PubMed PMID: 25549945.

16: Tigno-Aranjuez JT, Benderitter P, Rombouts F, Deroose F, Bai X, Mattioli B, Cominelli F, Pizarro TT, Hoflack J, Abbott DW. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease. J Biol Chem. 2014 Oct 24;289(43):29651-64. doi: 10.1074/jbc.M114.591388. Epub 2014 Sep 11. PubMed PMID: 25213858; PubMed Central PMCID: PMC4207980.

17: Woo JI, Oh S, Webster P, Lee YJ, Lim DJ, Moon SK. NOD2/RICK-dependent β-defensin 2 regulation is protective for nontypeable Haemophilus influenzae-induced middle ear infection. PLoS One. 2014 Mar 13;9(3):e90933. doi: 10.1371/journal.pone.0090933. eCollection 2014. PubMed PMID: 24625812; PubMed Central PMCID: PMC3953203.

18: Natarajan C, Yao SY, Zhang F, Sriram S. Activation of NOD2/RIPK2 pathway induces mitochondrial injury to oligodendrocyte precursor cells in vitro and CNS demyelination in vivo. J Neuroimmunol. 2013 Dec 15;265(1-2):51-60. doi: 10.1016/j.jneuroim.2013.09.009. Epub 2013 Oct 9. PubMed PMID: 24169446.

19: Damgaard RB, Fiil BK, Speckmann C, Yabal M, zur Stadt U, Bekker-Jensen S, Jost PJ, Ehl S, Mailand N, Gyrd-Hansen M. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med. 2013 Aug;5(8):1278-95. doi: 10.1002/emmm.201303090. Epub 2013 Jul 1. PubMed PMID: 23818254; PubMed Central PMCID: PMC3944466.

20: Fiil BK, Damgaard RB, Wagner SA, Keusekotten K, Fritsch M, Bekker-Jensen S, Mailand N, Choudhary C, Komander D, Gyrd-Hansen M. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol Cell. 2013 Jun 27;50(6):818-830. doi: 10.1016/j.molcel.2013.06.004. PubMed PMID: 23806334; PubMed Central PMCID: PMC4194427.